The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates by Tomasicchio, Michele et al.
1Scientific RepoRts | 617850 | DOI: 10.1038/srep17850
www.nature.com/scientificreports
The diagnostic accuracy of the 
MTBDRplus and MTBDRsl assays 
for drug-resistant TB detection 
when performed on sputum and 
culture isolates
Michele Tomasicchio1,*, Grant Theron2,1,*, Elize Pietersen1, Elizabeth Streicher2, 
Danielle Stanley-Josephs2, Paul van Helden2, Rob Warren2 & Keertan Dheda1,3
Although molecular tests for drug-resistant TB perform well on culture isolates, their accuracy using 
clinical samples, particularly from TB and HIV-endemic settings, requires clarification. The MTBDRplus 
and MTBDRsl line probe assays were evaluated in 181 sputum samples and 270 isolates from patients 
with culture-confirmed drug-sensitive-TB, MDR-TB, or XDR-TB. Phenotypic culture-based testing was 
the reference standard. Using sputum, the sensitivities for resistance was 97.7%, 95.4%, 58.9%, 61.6% 
for rifampicin, isoniazid, ofloxacin, and amikacin, respectively, whereas the specificities were 91.8%, 
89%, 100%, and 100%, respectively. MTBDRsl sensitivity differed in smear-positive vs. smear-negative 
samples (79.2% vs. 20%, p < 0.0001 for ofloxacin; 72.9% vs. 37%, p = 0.0023 for amikacin) but not 
by HIV status. If used sequentially, MTBDRplus and MTBDRsl could rule-in XDR-TB in 78.5% (22/28) 
and 10.5% (2/19) of smear-positive and smear-negative samples, respectively. On culture isolates, the 
sensitivity for resistance to rifampicin, isoniazid, ofloxacin, and amikacin was 95.1%, 96.1%, 72.3% and 
76.6%, respectively, whereas the specificities exceeded 96%. Using a sequential testing approach, rapid 
sputum-based diagnosis of fluoroquinolone or aminoglycoside-resistant TB is feasible only in smear-
positive samples, where rule-in value is good. Further investigation is required in samples that test 
susceptible in order to rule-out second-line drug resistance.
Tuberculosis (TB) remains a leading cause of morbidity and mortality in developing countries42. National and 
global TB control efforts are undermined by the emergence of drug-resistant TB. MDR-TB is defined as resistance 
to rifampicin [RIF] and isoniazid [INH], and extensively drug-resistant TB (XDR-TB) is defined as MDR-TB plus 
resistance to a fluoroquinolone [FLQ] and a second-line injectable drug, such as amikacin [AMK], or capreomyin 
[CAP]2,3. DR-TB is associated with high mortality4–7, is a threat to healthcare workers8,9, and results in unsustainable 
costs that destabilise national TB control programmes (NTPs)42,10. If patients are placed on effective treatment 
earlier11–13, which can be facilitated by rapid genotypic rather than the slower phenotypic diagnostic testing, trans-
mission will be reduced and the clinical prognosis of these patients will likely be improved.
In contrast to testing methods like the nitrate reductase assay14 and Microscopic Observation Drug Susceptibility 
(MODS)15, the MTBDRplus line probe assay (LPA; Hain Lifescience, Nehren, Germany), which is approved by the 
World Health Organisation (WHO) for the detection of RIF and INH resistance, is a same day test with a short 
relatively rapid within laboratory turn-around-time (~5 hours). It has an estimated sensitivity and specificity of 
98.1% and 98.7% for both RIF and INH, when performed on culture isolates16, however, there are limited data 
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about its performance using sputum. Several recent reports have reported a sensitivity of ~95% in smear-positive 
samples and ~65% in smear-negative samples17–21. Another LPA, MTBDRsl, was developed to diagnose XDR-TB 
by detecting mutations in the gyrA and rrs genes, thereby determining susceptibility to the FQs (ofloxacin, moxi-
floxacin, levofloxacin), and the second line injectable drugs (SLIDs; amikacin, kanamycin, and capreomycin). The 
assay displays a sensitivity and specificity of 85.1% and 98.2% to detect FQ resistance when performed directly 
(using smear-positive sputum samples)22, and 83.1% and 97.7, respectively when performed indirectly (using 
culture isolates)22. MTBDRsl exhibited sensitivities and specificities of 76.9% and 99.5% for the SLID class when 
performed indirectly (using isolates) and 94.4% and 98.2%, respectively when performed using smear-positive 
sputum samples (directly).
MTBDRsl makes the rapid same-day diagnosis of XDR-TB possible when it is used in combination with rapid 
tests for MDR-TB such as MTBDRplus. However, there are several gaps in our knowledge before such a strategy 
can be applied in appropriate settings. There are few data from a small number of cases about the performance of 
MTBDRsl using clinical samples23–25, none of which were smear-negative, and there are no studies evaluating the 
impact of HIV on accuracy. Moreover, a sequential testing strategy to inform clinical practice (e.g. MTBDRplus 
followed by MTBDRsl), and determinants of performance in this context, has hitherto not been evaluated. To 
address these considerations we evaluated the comparative diagnostic accuracy of the MTBDRplus and MTBDRsl 
assays using smear-positive and smear-negative sputum samples, and culture isolates obtained from patients in a 
TB and HIV endemic setting.
Methods
Study site and population. Sputum was collected from 234 patients enrolled in Brooklyn Chest Hospital, 
in Cape Town, South Africa, or undergoing routine testing at a centralised testing reference laboratory (National 
Health Laboratory Services [NHLS] at Groote Schuur Hospital). Brooklyn Chest Hospital is the designated pro-
vincial treatment centre for XDR-TB in the Western Cape. Brooklyn Chest Hospital also enrols patients with other 
types of drug-resistant TB. We accessed sputum or culture isolates from patients with culture-confirmed MDR-TB, 
or XDR-TB. The sputum samples and culture isolates came from different patients. Patients with confirmed drug 
susceptible isolates were sourced from the NHLS at Groote Schuur Hospital. DR-TB were based on phenotypical 
DST results. Patients were on anti-TB treatment at the time of specimen collection. In addition to the specimen 
collected for LPA testing, we collected a paired, second specimen that was used for microscopy and liquid culture. 
A HIV test was performed after appropriate counselling. This study was approved by the University of Cape Town 
Faculty of Health Sciences Ethics Committee and the methods were carried out in accordance with the approved 
guidelines. All patients provided written informed consent.
Specimen processing. Samples were processed using the standard NALC-NaOH method (final NaOH con-
centration 1%26). Smear microscopy was performed using Ziehl-Neelsen staining. The WHO-recommended critical 
concentrations for RIF (1 μ g/mL), INH (1 μ g/mL), AMK (1 μ g/mL) and ofloxacin (OFX) (2 μ g/mL), were used for 
DST using the MGIT 960 liquid culture system (BD Bioscience, Erebodegem, Belgium27).
MTBDRplus and MTBDRsl line probe assays. The MTBDRplus assay (version 1) and the MTBDRsl assay 
(version 1) were performed directly on a single sputum sediments. Sputum from 181 culture-positive patients 
received both tests. MTBDRplus and MTBDRsl were also performed indirectly on culture isolates (MTBDRplus and 
MTBDRsl; n = 270 received both tests) according to the manufacturer’s instructions (Hain Lifescience, Germany). 
The person performing the tests was blinded to the reference standard results. Manufacturer-recommended poly-
merase (HotStarTaq; Qiagen) was used for both LPAs, and the PCR on DNA from culture isolates was performed 
using the following parameters: 95 °C for 15 min, 95 °C for 30 s, 58 °C for 2 min (10 cycles), 95°C for 25 s, 53 °C 
for 40 s, 70 °C for 40 s (20 cycles) and final extension at 70 °C for 8 min (the parameters used for detecting DNA 
from sputum using the LPAs used 30 cycles of elongation). A valid LPA result was defined by a Mycobacterium 
tuberculosis complex-specific control (TUB), conjugate controls (CC) and amplification control (AC) bands in 
conjunction with the target gene locus control.
Discrepant analysis. Sequencing was performed on the inhA promoter, rpoB, katG, gyrA and rrs genes, from 
isolates that were discrepant between phenotypic DST and either of the LPAs. The sequences of the primers used 
can be found in supplementary Table S1.
Statistics. The sensitivity and specificity were calculated for each drug compared to the gold standard of 
culture-based DST. Patients whose paired sputum specimen was culture-negative were excluded. Statistical analyses 
were performed using Graphpad Prism (version 6.0; GraphPad Software, USA, www.graphpad.com), and STATA 
SE (version 12; StataCorp, USA). P-values less than 0.05 were considered significant. Fisher’s exact test with mid-P 
correction was used for comparisons between proportions.
Results
Patients and samples. The demographic data of the patients enrolled in the study is shown in Table 1. 
Demographic data was unavailable for 7/234 patients because of technical problems accessing the electronic 
NHLS records.
Figure 1 shows the study plan of the 234 patients tested using the LPAs. Fifty three patients were excluded 
because they were culture-negative. Of the 181 culture-positive samples, 45, 33, 56 and 47 were, according to 
phenotypic DST, DS-, MDR, MDR+ (MDR-TB and resistance to a FQ or SLID but did not meet the criteria for 
XDR-TB) and XDR, respectively.
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MTBDRplus performance. Direct testing of sputum samples by MTBDRplus. Accuracy: The diagnostic 
accuracy of MTBDRplus is shown in Table 2. The accuracy (sensitivity, specificity) for RIFR and INHR were (97.7%, 
91.8%) and (95.4%, 89%), respectively. When the discrepant results were resolved by sequencing, the accuracy 
(sensitivity, specificity %) to detect RIFR and INHR increased to (100%, 100%) and (97.7%, 97.4%), respectively.
Indeterminate rate: The indeterminate rates are shown in Fig. 1. Amongst the MTBDRplus-TUB-positive spu-
tum samples, 4% (5/129) were indeterminate. Twenty percent and 80% were smear-positive and smear-negative, 
respectively (p = 0.058).
Impact of HIV: Table 3 shows the sensitivities and specificities amongst samples from HIV-infected 
or -uninfected patients. The sensitivities and specificities to detect RIFR or INHR did not change according to 
HIV status.
Indirect testing of the culture isolates. Accuracy: The diagnostic accuracy of MTBDRplus for the culture isolates 
is shown in Table 4. The LPA had a sensitivity and specificity to detect RIFR of 95.1% (95% CI 92.2% to 98.1%) 
and 100%, respectively and a sensitivity and specificity of 96.1% (93.5% to 98.7%) and 96.1% (90.8% to 100%), 
respectively to detect INHR.
Indeterminate rate: The study plan for the 270 culture isolates is shown in Figure S1. From the 270 culture isolates 
tested, 95.2% (257/270) were TUB band-positive and all were MTBDRplus determinate. The indeterminate rate 
amongst the direct testing of the sputum samples (5/129) was significantly different to the indirect testing of the 
culture isolates (257/257; p < 0.001).
MTBDRsl performance. Direct testing of sputum samples by MTBDRsl. Accuracy: The diagnostic accu-
racy for MTBDRsl is shown in Table 2. Overall the LPA exhibited suboptimal sensitivity for OFXR (58.9% [95% CI 
47.6% to 70.2%]) and AMKR (61.6% [50.4% to 72.8%]). However, sensitivity was higher in smear-positive sputum 
samples (OFXR: 79.2% [95% CI 67.7% to 90.7%] and AMKR: 72.9% [60.3% to 85.5%], respectively; p = 0.473) 
compared to smear-negative sputum samples (OFXR: 20% [4.3% to 35.7%; p < 0.001] and AMKR: 37%; [18.8% to 
55.2%; p < 0.001]), respectively. MTBDRsl displayed excellent specificities of 100% to detect OFXR and AMKR in 
sputum. Furthermore, the sensitivities and specificities of MTBDRsl to detect OFXR and AMKR did not significantly 
change when the discordant results were resolved by sequencing.
Impact of HIV: The diagnostic accuracy of MTBDRsl when stratified according to HIV status is shown in Table 3. 
Similarly to MTBDRplus, the sensitivities and specificities of MTBDRsl amongst the samples from HIV-infected 
versus HIV-uninfected patients were not significantly different at 48.1% versus 64.1% (p = 0.197) and 94.4% ver-
sus 83.3% (p = 0.26) for OFXR and 59.2% versus 64.2% (p = 0.690) and 100% versus 90% (p = 0.166) for AMKR.
Indeterminate rate: Figure 1 shown that indeterminate rates for MTBDRsl. From the 153 TUB-positive sputum 
samples tested by MTBDRsl, 14.4% (22/153) were indeterminate, of which 64% (14/22) and 36% (8/22) were 
smear-positive and smear-negative, respectively (p = 0.070). The overall indeterminate rates are depicted in Table 2. 
Of the MTBDRsl TUB-positive results from smear-positive samples 1.6% (2/122) were indeterminate, compared 
to 5.1% (3/59) from smear-negative samples (p = 0.185).
Indirect testing of the culture isolates. Accuracy: The accuracy of MTBDRsl for the culture isolates is shown in 
Table 4. Indirect testing of the culture isolates by MTBDRsl showed a sensitivity and specificity of 72.3% (115/159) 
and 99% (100/101) for OFXR, respectively. For AMKR the sensitivity and specificity was 76.6% (125/157) and 98% 
(99/101), respectively.
Demographic data Study Cohort (%) (n = 227)*
Age
 Mean years (range) 37 (18–111)
Sex
 Male 110 (48)
 Female 117 (52)
Race
 Black 109 (48)
 Mixed 118 (52)
HIV-infected
 Yes 107 (47)
 No 113 (50)
 Unknown 7 (3)
 CD4 count (cells/mL) rangeΨ 308 (2–983)
Table 1.  Demographic data of the cohorts used in study. *Demographic data for 7 patients was missing.
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Indeterminate rate: The study plan of the culture isolates is shown in Figure S1. From the 270 culture isolates 
tested indirectly by MTBDRsl, 97% (262/270) were TUB band-positive and all were determinate. The proportion 
of indeterminate results for MTBDRsl between direct testing of sputum (14.4% [22/153]) and indirect testing of 
isolates (0% [262/262]; p < 0.001) was statistically different.
Comparison of direct and indirect testing for MTBDRsl. A comparison of the accuracy for the culture isolates versus 
the sputum samples using MTBDRsl is shown in Tables 4 and 2, respectively. MTBDRsl had increased sensitivity to 
detect OFXR indirectly on the culture isolates (72.3% [115/159]) compared to direct testing of the sputum samples 
(58.9% [43/73]; p = 0.042). MTBDRsl had an improved sensitivity to detect AMKR indirectly (76.6% [125/157] 
versus directly on sputum (61.6% [54/73]; p = 0.004).
Figure 1. Study plan showing the number of sputum samples tested directly using MTBDRplus (version 1)  
or MTBDRsl (version 1) according to patients’ diagnoses and smear-status. The diagnosis was obtained 
using phenotypic liquid culture-based DST on a specimen collected at the same time as the specimen used for 
the line probe assays. A test is classified as positive for the Mycobacterium tuberculosis complex by the presence 
of the M. tb complex band (TUB), while a test is classified as negative by the absence of the M. tb complex band 
(TUB). Indeterminate results are those which are TUB-band positive yet are missing controls bands for gene 
specific loci. TB = tuberculosis; DS = drug sensitive, MDR = multi drug resistant, MDR+ =  MDR-TB but with 
additional resistance to OFX, KAN or INH. XDR = extensively drug resistant.
All sputum samples Smear-positive sputum Smear-negative sputum
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
MTBDRplus‡  
(v 1.0)
RIFR * 97.7 (86/88) 91.8 (34/37) 97.1 (69/71) 91.2 (31/34) 100 (17/17) (p = 0.484) 100 (3/3)
INHR * 95.4 (84/88) 89 (33/37) 95.6 (68/71) 88.2 (30/34) 94.1 (16/17) (p = 0.768) 100 (3/3)
MTBDRsl †  
(v 1.0)
OFXR 58.9 (43/73) 100 (38/38) 79.2 (38/48) 100 (34/34) 20 (5/25) (p < 0.001) 100 (4/4)
AMKR 61.6 (45/73)  100 (38/38) 72.9 (35/48) 100 (34/34) 37 (10/27) (p < 0.001) 100 (4/4)
Table 2.  Diagnostic accuracy of MTBDRplus and MTBDRsl for the direct detection of drug resistance 
in sputum samples using phenotypic culture-based susceptibility testing as a reference standard. ‡ 7.4% 
(9/122) MTBDRplus results from smear-positive samples were indeterminate, compared to 17% (10/59) from 
smear-negative (p = 0.049). †1.6% (2/122) MTBDRsl results from smear-positive samples were indeterminate, 
compared to 5.1% (3/59) from smear-negative (p = 0.185). Refer to the materials and methods for a description 
of what defines an indeterminate result. P-values are for comparisons between smear statuses. *When the 
discrepant results were resolved by sequencing the sensitivities and specificities of MTBDRplus were 100% 
and 100% to detect RIFR, respectively and 97.7% and 97.4% to detect INHR, respectively. RIFR = rifampicin 
resistance, INHR  = isoniazid resistance, OFXR  =  ofloxacin resistance, AMKR  = amikacin resistance.
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XDR-TB diagnosis by sequential use of MTBDRplus and MTBDRsl on sputum samples. Overall: 
Fig. 2A, depicts the ability of MTBDRsl to detect XDR-TB when performed directly and in conjunction with 
MTBDRplus. From the 47 culture-positive and phenotypically-confirmed XDR sputum samples, all 47 were determi-
nate for MTBDRplus and 31 of these were detected as MDR-TB (RIF and INH resistant). Of these 31, 93.3% (28/30) 
were MTBDRsl-determinate and 23 were detected as XDR-TB (resistance to OFX and AMK). When used sequen-
tially on sputum samples, MTBDRplus and MTBDRsl could thus rule in 49% (23/47 [95% CI 34.71% to 63.29%) of 
XDR-TB samples. The sequential use of MTBDRplus and MTBDRsl to detect XDR-TB when stratified according to 
smear-positive or smear-negative samples is shown in Fig. 2B. This testing strategy could rule in 78.5% (22/28) of 
smear-positive XDR-TB samples and 10.5% (2/19; p < 0.001) of smear-negative XDR-TB samples. The lower rule-in 
value in smear-negative samples is due to the high indeterminate rate relative to the smear-positive specimens.
Discussion
We evaluated the diagnostic accuracy of MTBDRplus and MTBDRsl using sputum samples and culture isolates. 
There are hardly any data comparing the accuracy of MTBDRsl in smear-positive and smear-negative samples 
or interrogating the impact of HIV status. We show that MTBDRplus has excellent sensitivity for both RIFR and 
INHR using smear-positive and smear-negative sputum samples. By contrast, MTBDRsl showed modest sensitivity 
for OFX and AMK resistance in sputum samples. However, sensitivity was markedly reduced in smear-negative 
versus smear-positive sputum samples and indeterminate rates were elevated. Both LPAs had high specificity for 
the detection of drug-specific resistance, and thus a positive result for resistance can be treated with confidence.
This is the first study to evaluate the diagnostic accuracy of MTBDRsl directly on smear-negative clinical spu-
tum samples. This information is critical to initiate rapid treatment and minimise transmission in areas with high 
HIV and TB co-infection where most patients are smear-negative28. Furthermore, although Xpert MTB/RIF can 
predict smear status29–31, the initial smear status of patients is often unknown and it can be unclear what DR-TB 
testing modality is suitable for sputum.
Sensitivities for OFXR and AMKR in sputum were lower than that published previously in our setting32, how-
ever, our study was the first to use smear-negative specimens. The reduced sensitivity of MTBDRsl amongst 
smear-negative samples indicate that, when used directly MTBDRsl, will likely only be useful in smear-positive 
sputum. The low sensitivity in smear-negative sputum can be explained by low concentrations of bacilli in the 
sputum, which are below the detection limit of the LPA33.
When performed indirectly on the culture isolates no MTBDRplus and MTBDRsl-TUB band positive results 
were indeterminate. However, when performed directly on the sputum samples, 4% of the MTBDRplus-TUB 
band positive results were indeterminate. By contrast, MTBDRsl had a high number of indeterminate results when 
performed directly at 14.4% (22/153). This is higher than has been reported in other studies22 and is explained by 
the testing of smear-negative samples, which harboured the bulk of the indeterminate (36%) readouts34.
All sputum samples Smear-positive sputum Smear-negative sputum
HIV-infected HIV-uninfected HIV-infected HIV-uninfected HIV-infected HIV-uninfected
Sensitivity 
(%)
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
Sensitivity 
(%)
Specificity 
(%)
MTBDRplus  
(v 1.0)
RIFR 96.7 (29/30) 90 (9/10)
98 (49/50) 
(p = 0.712)
88.2 
(15/17) 
(p = 0.888)
100 
(23/23) 100 (8/8)
97.7 
(43/44) 
(p = 0.466)
100 
(14/14) 100 (7/7) 100 (1/1) 100 (8/8) 100 (1/1)
INHR 93.3 (28/30) 90 (9/10)
96 (48/50) 
(p = 0.596)
88.2 
(15/17) 
(p = 0.888)
91.6 
(22/24) 100 (8/8)
97.6 
(41/42) 
(p = 0.264)
50 (2/4) 100 (7/7) 100 (1/1) 87.5 (7/8) (p = 0.333) 100 (1/1)
MTBDRsl  
(v 1.0)
OFXR 48.1 (13/27)
94.4 
(17/18)
64.1 
(25/39) 
(p = 0.197)
83.3 
(25/30) 
(p = 0.260)
69 (11/16) 100 (9/9)
82.1 
(23/28) 
(p = 0.308)
100 
(17/17) 18.2 (2/11) 100 (2/2) 18.2 (2/11) 100 (1/1)
AMKR 59.2 (16/27)
100 
(18/18)
64.1 
(25/39) 
(p = 0.690)
90 (27/30) 
(p = 0.166)
62.5 
(10/16) 100 (9/9)
78.6 
(22/28) 
(p = 0.250)
100 
(17/17) 50 (6/12) 100 (2/2)
27.3 (3/11) 
(p = 0.265) 100 (1/1)
Table 3.  Diagnostic accuracy of MTBDRplus and MTBDRsl for the direct detection of drug resistance 
in sputum samples according to HIV status compared to phenotypic culture-based susceptibility testing 
(reference standard). P-values are for comparisons between HIV statuses. RIFR = rifampicin resistance, 
INHR = isoniazid resistance, OFXR = ofloxacin resistance, AMKR = amikacin resistance.
Sensitivity (%) Specificity (%)
MTBDRplus (v 1.0)
RIFR 95.1% (196/206) (p = 0.117) 100% (51/51) (p = 0.039)
INHR 96.1% (198/206) (p = 0.495) 96.1% (49/51) (p = 0.698)
MTBDRsl (v 1.0)
OFXR 72.3% (115/159) (p = 0.042) 99.0% (100/101) (p = 0.538)
AMKR 76.6% (125/157) (p = 0.004) 98.0% (99/101) (p = 0.382)
Table 4.  Diagnostic accuracy of MTBDRplus and MTBDRsl for the detection of drug resistance in culture 
isolates compared to phenotypic culture-based susceptibility testing (reference standard). P-values are for 
comparisons between direct testing on specimens (both smear-positive and smear-negative; data shown in Table 2).
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This is the first study to evaluate a sequential testing strategy. The data is shown in Figs S2 and 2. We show that 
when MTBDRplus and MTBDRsl are used sequentially on DST culture-confirmed MDR+ or XDR-TB samples, 
the assays could rule-in 60%, 62.5% and 49% of OFX mono-resistant, AMK mono-resistant, and XDR-TB sam-
ples, respectively. When used sequentially on smear-positive XDR-TB samples, the assays could rule-in 78.6% of 
cases. However, the ability of the assay to accurately rule-in XDR-TB samples amongst the smear-negative sputum 
samples (10.5%) was substantially lower.
Overall our data indicate that MTBDRsl is likely a useful tool to rapidly diagnose MDR+ and XDR-TB, but 
only in smear-positive sputum samples. This is useful from a clinical and public health perspective as it enables a 
more rapid diagnosis (potentially by several weeks) thus likely minimising patient morbidity and mortality32, and 
most importantly ongoing transmission in the community. Transmission of DR-TB explains almost 80% of new 
cases in South Africa35 and has led to the emergence and transmission of resistance beyond XDR-TB36–38. We are 
of the view that the MTBDRsl assay should be used routinely in high MDR-TB burden programmatic settings in 
patients with rifampicin resistance. However, we acknowledge that further studies are urgently needed in different 
settings to confirm our findings so that global recommendations can be made that apply to high MDR-TB settings 
including South Africa and Eastern Europe. Our study represents the first step in this direction.
There are several limitations to our work. MTBDRplus version 1 and MTBDRsl version 1 were used, which 
have recently been succeeded by a new iteration (version 2)39,40. Nevertheless, diagnostic accuracy of MTBDRplus 
was excellent in the clinical sputum samples and similar to recent studies where version 2 of MTBDRplus was 
shown to have comparable accuracy to Xpert MTB/RIF in smear-negative sputum39,41. Both MTBDRplus and 
MTBDRsl were not performed at initial diagnosis, however, we collected a paired specimen for culture in order 
to control for the viability of the bacilli. Our samples size, particularly of the smear-negative group were small, yet 
substantially more than what has been reported elsewhere21–25. We also lacked data on the duration of treatment 
for each patient. A further limitation to the study was that both LPAs were only tested on culture-positive and not 
culture-negative sputum samples. There were 5 smear-positive culture-negative samples and these were excluded 
from the analysis given that they did not meet the reference standard definition. Finally, we did not test the impact 
of using MTBDRplus and MTBDRsl on treatment outcomes, cure, and death of the patients. However, our work 
lays the foundation for confirmatory and impact studies to now be undertaken.
In conclusion, even though MTBDRsl had suboptimal diagnostic sensitivity for OFXR and AMKR, it remains an 
important rule-in tool to rapidly detect XDR-TB and MDR+ TB using smear-positive clinical samples, given that 
alternative tests have a prolonged within-laboratory turn-around-time and are technically challenging. Negative 
results, however, require further investigation as resistance to second line drugs may still be present but undetected 
by the assay. Smear-negative sputum specimens should be cultured prior to MTBDRsl testing.
Figure 2. The testing pathway for the diagnosis of XDR-TB overall (A) or according to smear-status (B) in the 
clinical sputum specimens, when MTBDRplus and MTBDRsl were used sequentially. From the 234 sputum 
specimens tested, 47 culture-positive samples were diagnosed as XDR-TB by phenotypic DST.
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